Dose‐ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti‐cancer chemotherapy Academic Article Article uri icon

Overview

MeSH Major

  • Amyotrophic Lateral Sclerosis
  • Biomarkers
  • Muscle Weakness
  • Nerve Growth Factors
  • Neuropeptides

abstract

  • Tropisetron can be administered safely in the doses tested with no dose-limiting toxicities. The encouraging antiemetic efficacy, mild toxicities, lack of extrapyramidal effects, and convenience of a single 15-minute infusion regimen make this drug appropriate for study in additional trials.

publication date

  • January 1993

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1002/1097-0142(19930101)71:1<226::AID-CNCR2820710135>3.0.CO;2-T

PubMed ID

  • 8416720

Additional Document Info

start page

  • 226

end page

  • 30

volume

  • 71

number

  • 1